

RESEARCH ARTICLE

Whole Genome Sequencing Reveals a De Novo *SHANK3* Mutation in Familial Autism Spectrum Disorder

Sergio I. Nemirovsky^{1‡}, Marta Córdoba^{4‡}, Jonathan J. Zaiat¹, Sabrina P. Completa¹, Patricia A. Vega⁴, Dolores González-Morón⁴, Nancy M. Medina⁴, Mónica Fabbro², Soledad Romero², Bianca Brun², Santiago Revale², María Florencia Ogara⁵, Adali Pecci⁵, Marcelo Marti^{1,3}, Martín Vazquez², Adrián Turjanski^{1,3}, Marcelo A. Kauffman^{4*}

1 Plataforma de Bioinformática Argentina, Instituto de Cálculo, Pabellón 2, Ciudad Universitaria, Facultad de Ciencias Exactas y Naturales, UBA, Buenos Aires, Argentina, **2** Instituto de Agrobiotecnología de Rosario (INDEAR), CONICET, Predio CCT, Rosario, Argentina, **3** Departamento de Química Biológica, Pabellón 2, Ciudad Universitaria, Facultad de Ciencias Exactas y Naturales, UBA, INQUIMAE/CONICET, Buenos Aires, Argentina, **4** Consultorio y Laboratorio de Neurogenética. Hospital JM Ramos Mejía. IBCN Eduardo de Robertis UBA-CONICET, Buenos Aires, Argentina, **5** Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, IFIBYNE-CONICET, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires, Argentina

‡ These authors contributed equally to this work.

* marcelokauffman@gmail.com



click for updates

OPEN ACCESS

Citation: Nemirovsky SI, Córdoba M, Zaiat JJ, Completa SP, Vega PA, González-Morón D, et al. (2015) Whole Genome Sequencing Reveals a De Novo *SHANK3* Mutation in Familial Autism Spectrum Disorder. PLoS ONE 10(2): e0116358. doi:10.1371/journal.pone.0116358

Academic Editor: Valerie W. Hu, The George Washington University, UNITED STATES

Received: June 6, 2014

Accepted: December 5, 2014

Published: February 3, 2015

Copyright: © 2015 Nemirovsky et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: This work was supported by an unrestricted grant from the Ministry of Science and Technology of the government of Argentina. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

Abstract

Introduction

Clinical genomics promise to be especially suitable for the study of etiologically heterogeneous conditions such as Autism Spectrum Disorder (ASD). Here we present three siblings with ASD where we evaluated the usefulness of Whole Genome Sequencing (WGS) for the diagnostic approach to ASD.

Methods

We identified a family segregating ASD in three siblings with an unidentified cause. We performed WGS in the three probands and used a state-of-the-art comprehensive bioinformatic analysis pipeline and prioritized the identified variants located in genes likely to be related to ASD. We validated the finding by Sanger sequencing in the probands and their parents.

Results

Three male siblings presented a syndrome characterized by severe intellectual disability, absence of language, autism spectrum symptoms and epilepsy with negative family history for mental retardation, language disorders, ASD or other psychiatric disorders. We found germline mosaicism for a heterozygous deletion of a cytosine in the exon 21 of the *SHANK3* gene, resulting in a missense sequence of 5 codons followed by a premature stop codon (NM_033517:c.3259_3259delC, p.Ser1088Profs*6).

Conclusions

We reported an infrequent form of familial ASD where WGS proved useful in the clinic. We identified a mutation in *SHANK3* that underscores its relevance in Autism Spectrum Disorder.

Introduction

Autism spectrum disorder (ASD) is a common cause of early disability, affecting about 1% of the population. It is characterized by impairments in social interaction and communication, as well as by repetitive and restricted behaviors [1].

ASD is etiologically heterogeneous, with hundreds of highly penetrant genetic aberrations involved as causative factors. Among them, *SHANK3* haploinsufficiency has been identified in about 0.5% of subjects with ASD. However, few familial ASD cases caused by mutations in *SHANK3* have been identified [2]. Here we present three siblings with ASD where Whole Genome Sequencing (WGS), identified germline mosaicism for a new mutation in *SHANK3*.

Methods

Study participants

The Ethics Committee of Hospital Ramos Mejía in Buenos Aires, Argentina approved this study. Written informed consents were obtained from the parents of the probands. Clinical investigation was conducted according to the principles expressed in the Declaration of Helsinki. The parents of the individuals described in this manuscript gave written informed consent to publish these case details. DNA sequencing data remained stored in a secure internal database, and is available upon request to researchers wishing to use them for research purposes only. Clinical evaluations were performed at the Neurogenetics Unit from Hospital Ramos Mejía.

Genome sequence data generation

Genomic DNA was isolated from peripheral blood and sequenced using 101 base-pair paired-end reversible terminator massively parallel sequencing on an Illumina HiSeq 1500 instrument at INDEAR (Rosario, Argentina), following sequencing library preparation in agreement to standard Illumina protocols. Median fragment length of the libraries was 294 bp. A total of 334.1 Gb with quality equal or more than Q30 was produced for the three genomes. Specifically, 575,427,640 paired-end reads were produced for proband 1 (35.5X coverage), 603,002,568 paired-end reads were produced for proband 2 (37.18X coverage) and 527,754,644 paired-end reads were produced for proband 3 (32.58X coverage).

Sequence Alignment and Annotation

Paired-end reads obtained from sequencing the probands' whole genomes were aligned to the GRCh37 reference human genome using the Burrows-Wheeler Alignment Tool (BWA) [3]. The resulting SAM files were realigned and recalibrated by implementation of the Genome Analysis Toolkit (GATK) framework [4,5]. Variant calling was performed using the Unified Genotyper tools from GATK. Variant annotation and effect prediction was carried out with SnpEff 3.5a (build 2014-02-14) [6,7] with data from dbSNP Build 138 [8], the 1000 Genomes Project [9], the International HapMap Project [10], the NHGRI GWAS Catalog [11], dbNSFP v2.3 [12,13], the Exome Sequencing Project (ESP) [14], and ClinVar Build 20140211 [15]. See [S1 Fig](#).

Bioinformatic Prioritization of candidate variants (see [Table 1](#))

Only high-quality variants (i.e. not filtered out by the GATK's Variant Quality Score Recalibration method) were considered for the analysis. Those with recorded population frequencies estimates higher than 1% (data from the 1000 Genomes Project and the Exome Sequencing Project) were also discarded as unlikely to be of relevance. From this remaining set, variants with high probability of affecting gene function (frame-shift, nonsense, missense, affecting splice sites and small insertions and deletions) were grouped according to 3 different models of inheritance that may explain the probands' phenotype: a recessive model grouped homozygous variants or compound heterozygous candidate variants present in the somatic chromosomes, a X-linked model grouped variants from the X chromosome, and a *high impact and rare variants* model grouped only high impact (nonsense, frame-shift, splice site changes) variants not recorded in the available databases. These groups were filtered through a list of 182 genes known to be of relevance in ASD according to SFARI database [16] ([S1 Table](#)).

Manual Review of Candidate variants

After prioritization, variants considered to possibly explain the phenotype were further investigated individually through the use of several databases and functional evaluation tools which included those provided by NCBI (www.ncbi.nlm.nih.gov), ENSEMBL [17] (www.ensembl.org/index.html), Mutation Taster [18] (www.mutationtaster.org), the Combined Annotation Dependent Depletion framework [19] (cadd.gs.washington.edu) and the Search Tool for the Retrieval of Interacting Genes/Proteins [20] (STRING; string-db.org), among others.

Table 1. Summary of variants in the 3 genomes.

	Proband 1 (III-1)	Proband 2 (III-2)	Proband 3 (III-3)	Shared
Reads	1,150,855,280	1,206,005,136	1,055,509,288	-
High Confidence (HC) Variants	4,157,729	4,152,776	4,155,158	3,153,415
HC Variants in Coding Regions*	24,319	23,882	23,939	18,394
HC Variants at Splice sites**	467	450	447	351
HC Single Nucleotide Variants (SNV)	3,556,615	3,547,621	3,543,994	2,750,765
HC Short Indels	601,114	605,155	611,164	402,650
HC Variants in ASD gene's list	71,348	69,173	69,215	53,358
HC Variants compliant to the Recessive Model	438	395	394	145
Genes with HC variants compliant to the Recessive Model	207	198	194	86
HC Variants in in ASD genes and compliant with the Recessive Model	2	1	1	1
ASD genes with HC Variants compliant with the Recessive Model	2	1	1	1
HC Variants compliant to the X-Linked Model	16	11	10	5
Genes with HC variants compliant to the X-Linked Model	14	10	9	4
HC Variants in in ASD genes and compliant with the X-Linked Model	1	0	0	0
ASD genes with HC Variants compliant with the X-Linked Model	1	0	0	0
HC Variants compliant to the High Impact De Novo Model	24	35	28	6
Genes with HC variants compliant to the High Impact De Novo Model	23	35	27	6
HC Variants in ASD genes and compliant with the High Impact De Novo Model	1	1	1	1
ASD genes with HC Variants compliant with the High Impact De Novo Model	1	1	1	1

* Including all changes within coding regions (synonymous and nonsynonymous substitutions and short insertions and deletions)

** Defined as 2 bases after exon end or 2 bases before exon start (only measured in introns).

doi:10.1371/journal.pone.0116358.t001

Results

Case Descriptions

Three male siblings were included in this study. All of them presented a syndrome characterized by severe intellectual disability, absence of language, autism spectrum symptoms and epilepsy. Family history was otherwise negative for mental retardation, language disorders, ASD or other psychiatric disorders. They were the sole offspring of healthy and unrelated parents after full-term and uneventful pregnancies (Fig. 1A). The mother performed appropriate health checks during gestations and she didn't show any pathological findings. Deliveries and birth parameters were unremarkable. The eldest proband (III-1 in Fig. 1A) was symptomatic since birth. Neonatal hypotonia was manifested by sucking difficulties and a mild delay in motor development. He had limited eye contact since 6 months of age. He never developed a functional language. He showed severe behavioral problems, motor stereotypes and circumscribed interests since the age of four. He developed epilepsy at the age of 6, suffering from frequent atonic seizure non-respondent to classical antiepileptic drugs. The younger siblings (III-2 and III-3) showed very similar clinical features. They shared dysmorphic features: broad nasal bridge, bulbous nasal root and macrostomia. They exhibited no neonatal hypotonia and showed normal development during their first two years of life with no observable alterations in language. A progressive deterioration started after this age. Language development was arrested, evolving




Figure 1. A SHANK3 point mutation in three siblings with Autism Spectrum Disorder. A) Family pedigree depicting the three probands (III-1, III-2, III-3), parents, their siblings and grandparents. B) Mutation as evidenced by whole genome sequencing compared to reference sequence (GRCh37) at bottom. Broad lines represent aligned reads. The heterozygous deletion is depicted as black, thin lines that interrupt the reads. Each panel depicts the data from one proband. C) Capillary sequencing chromatograms of the probands and their parents. A red arrow signals the position of the deletion. The change in ORF is evidenced by the presence of double peaks after the deletion site caused by heterozygosity. D) Linear representations of the intact SHANK3 protein featuring its major domains and the presumptive protein if translated from the mutated sequence. ANK: ankyrin repeats, SH3: SH3 domain, PDZ: PDZ domain, Pro: Proline-rich region, SAM: Sterile alpha motif domain.

doi:10.1371/journal.pone.0116358.g001

to an almost complete absence of verbal communication. Social interaction became severely impaired. Agitation and repetitive motor behaviors were present since the age of three. Epilepsy with frequent atonic and generalized seizures refractory to medical treatment started at the age of 7 in both siblings. MRIs were normal and some of the several EEGs done showed right-temporal discharges. Standard karyotype and fragile X testing were normal in the three siblings.

Whole Genome Analysis

We performed whole genome sequencing of DNA samples from the three siblings, obtaining a mappable yield of 334.1 Gb, which represent an average depth of coverage of 33.04x. We identified more than 4.1 millions of variants in each genome (Table 1). We examined those rare variants (population frequency lower than 1%) in 182 genes associated to ASD (S1 Table) under three possible models of inheritance: *recessive*, *X-linked*, *high impact de novo mutations* (S2 Table, S3 Table). The most plausible candidate to explain the phenotype exhibited by the probands was a heterozygous deletion of a cysteine in the exon 21 of the *SHANK3* gene (Fig. 1, B), resulting in a missense sequence of 5 codons followed by a premature stop codon (NM_033517:c.3259_3259delC, p.Ser1088Profs*6). We did not find any difference in *SHANK3* mRNA levels in blood among the three affected siblings, their parents and two unrelated controls, suggesting an absence of effect at the transcription level. Therefore, when expressed this protein would lack a Proline-rich region and the Sterile alpha motif (SAM) domain (Fig. 1, D) resulting in a functional haploinsufficiency of *SHANK3* protein. Sanger sequencing confirmed this deletion in the three siblings and their absence in DNA purified from blood samples of both parents suggesting germinal mosaicism as the origin of the mutation (Fig. 1, C).

Discussion

Gene mutations can be identified in about 20% of individuals with ASD [21]. *SHANK3* aberrations have consistently been associated with idiopathic and syndromic ASD. However, point mutations in *SHANK3* have been rarely reported. A few patients were previously described with only one showing familial recurrence. It has been suggested that nonsense and frameshift mutations in this gene lead to more severe phenotypes [22] affecting language and development as it was observed in our patients. Moreover, a recent and exhaustive report on the effect of different mutations in the *SHANK* family of genes in ASD concluded that *SHANK3* mutations are probably the most prevalent etiology of ASD with mental retardation and among the different cases described there it is noteworthy to highlight one that have a frameshift deletion predicted to result in a truncated protein lacking the same functional domains that we predict for our mutation, thereby supporting a pathogenic role for the variant here described, precluding the need for more thorough functional assays [23]. The product of this gene is expressed at postsynaptic densities of excitatory glutamatergic synapses and it is involved in synaptic maturation [24]. Moreover, pharmacological restoring of its deficiency is current object of therapeutic research in ASD [25].

The use of WGS in the clinic is called to be transformative, especially in a complex etiologically heterogeneous disorder such as ASD and intellectual disability [26]. However, recent studies have questioned its readiness for diagnostic adoption mostly because of uncertainties associated with the analysis of such vast amount of information [27]. We have ruled out many variants with a predicted high-impact on protein function because we opted to focus our analysis on genes considered to be of relevance for the phenotype studied therefore decreasing interpretation uncertainties. This left the reported *SHANK3* mutation as the sole variant putatively

relevant to the phenotype showed in our patients. It is noteworthy to mention that by identifying the pathogenic variant causing the disorder segregating in this family, almost a decade of anxiety associated with diagnostic uncertainties could be alleviated. However, even though we could explain the recurrence of the disorder in the three siblings with the presence of germline mosaicism we could not estimate future recurrence risk because the proportion of germ cells mutated could not be quantified.

In summary, we reported an infrequent form of familial ASD where WGS proved useful in the clinic.

Supporting Information

S1 Fig. Flow diagram of the analysis. Reads resulting from Whole Genome Sequencing were aligned to the reference genome (GRCh37) with BWA and followed by realignment and recalibration with the Genome Analysis Toolkit (GATK). Variant calling was performed with the Unified Genotyper tool from the GATK, and annotated with SnpEff (see [S1 Methods](#)). After the whole variants set was produced, variants shared by the 3 probands were filtered if they presented population frequencies higher than 1% and according to the inheritance models described in Methods. These sets were then filtered by the ASD genes lists (see [S1 Table](#)) and manually reviewed for validation. Also, variants resulting from the first filter but not present after the second filter were manually screened and discarded if they showed no relation to the probands phenotype.

(TIF)

S1 Methods.

(DOCX)

S1 Table. Candidate genes.

(DOCX)

S2 Table. Inheritance Models.

(DOCX)

S3 Table. High impact High confidence intersection Variants.

(XLSX)

Author Contributions

Conceived and designed the experiments: SIN MC MFO AP MM MV AT MAK. Performed the experiments: SIN MC JJZ SPC NMM MF BB S. Romero S. Revale MFO AP MM MV AT MAK. Analyzed the data: SIN MC JJZ SPC NMM MFO AP MM MV AT MAK. Contributed reagents/materials/analysis tools: SIN MC PAV DG MM MV AT MAK. Wrote the paper: SIN MC MM MV AT MAK.

References

1. Lai M-C, Lombardo MV, Baron-Cohen S (2014) Autism. *The Lancet* 383: 896–910. doi: [10.1016/S0140-6736\(13\)61539-1](https://doi.org/10.1016/S0140-6736(13)61539-1) PMID: [24074734](https://pubmed.ncbi.nlm.nih.gov/24074734/)
2. Betancur C, Buxbaum JD (2013) *SHANK3* haploinsufficiency: a “common” but underdiagnosed highly penetrant monogenic cause of autism spectrum disorders. *Mol Autism* 4: 17. doi: [10.1186/2040-2392-4-17](https://doi.org/10.1186/2040-2392-4-17) PMID: [23758743](https://pubmed.ncbi.nlm.nih.gov/23758743/)
3. Li H, Durbin R (2010) Fast and accurate long-read alignment with Burrows-Wheeler transform. *Bioinformatics* 26: 589–595. doi: [10.1093/bioinformatics/btp698](https://doi.org/10.1093/bioinformatics/btp698) PMID: [20080505](https://pubmed.ncbi.nlm.nih.gov/20080505/)

4. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, et al. (2010) The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res* 20: 1297–1303. doi: [10.1101/gr.107524.110](https://doi.org/10.1101/gr.107524.110) PMID: [20644199](https://pubmed.ncbi.nlm.nih.gov/20644199/)
5. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, et al. (2011) A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nat Genet* 43: 491–498. doi: [10.1038/ng.806](https://doi.org/10.1038/ng.806) PMID: [21478889](https://pubmed.ncbi.nlm.nih.gov/21478889/)
6. Cingolani P, Platts A, Wang LL, Coon M, Nguyen T, et al. (2012) A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff. *Fly (Austin)* 6: 80–92. doi: [10.4161/fly.19695](https://doi.org/10.4161/fly.19695) PMID: [22728672](https://pubmed.ncbi.nlm.nih.gov/22728672/)
7. Ruden DM, Cingolani P, Patel VM, Coon M, Nguyen T, et al. (2012) Using *Drosophila melanogaster* as a model for genotoxic chemical mutational studies with a new program, SnpSift. *Toxicogenomics* 3: 35. doi: [10.3389/fgene.2012.00035](https://doi.org/10.3389/fgene.2012.00035) PMID: [22435069](https://pubmed.ncbi.nlm.nih.gov/22435069/)
8. Sherry ST, Ward M-H, Kholodov M, Baker J, Phan L, et al. (2001) dbSNP: the NCBI database of genetic variation. *Nucleic Acids Res* 29: 308–311. doi: [10.1093/nar/29.1.308](https://doi.org/10.1093/nar/29.1.308) PMID: [11125122](https://pubmed.ncbi.nlm.nih.gov/11125122/)
9. Consortium T 1000 GP (2012) An integrated map of genetic variation from 1,092 human genomes. *Nature* 491: 56–65. doi: [10.1038/nature11632](https://doi.org/10.1038/nature11632) PMID: [23128226](https://pubmed.ncbi.nlm.nih.gov/23128226/)
10. Gibbs RA, Belmont JW, Hardenbol P, Willis TD, Yu F, et al. (2003) The International HapMap Project. *Nature* 426: 789–796. doi: [10.1038/nature02168](https://doi.org/10.1038/nature02168) PMID: [14685227](https://pubmed.ncbi.nlm.nih.gov/14685227/)
11. Welter D, MacArthur J, Morales J, Burdett T, Hall P, et al. (2014) The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. *Nucleic Acids Res* 42: D1001–D1006. doi: [10.1093/nar/gkt1229](https://doi.org/10.1093/nar/gkt1229) PMID: [24316577](https://pubmed.ncbi.nlm.nih.gov/24316577/)
12. Liu X, Jian X, Boerwinkle E (2011) dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. *Hum Mutat* 32: 894–899. doi: [10.1002/humu.21517](https://doi.org/10.1002/humu.21517) PMID: [21520341](https://pubmed.ncbi.nlm.nih.gov/21520341/)
13. Liu X, Jian X, Boerwinkle E (2013) dbNSFP v2.0: A Database of Human Non-synonymous SNVs and Their Functional Predictions and Annotations. *Hum Mutat* 34: E2393–E2402. doi: [10.1002/humu.22376](https://doi.org/10.1002/humu.22376) PMID: [23843252](https://pubmed.ncbi.nlm.nih.gov/23843252/)
14. Fu W, O'Connor TD, Jun G, Kang HM, Abecasis G, et al. (2013) Analysis of 6,515 exomes reveals the recent origin of most human protein-coding variants. *Nature* 493: 216–220. doi: [10.1038/nature11690](https://doi.org/10.1038/nature11690) PMID: [23201682](https://pubmed.ncbi.nlm.nih.gov/23201682/)
15. Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, et al. (2013) ClinVar: public archive of relationships among sequence variation and human phenotype. *Nucleic Acids Res*: gkt1113. doi: [10.1093/nar/gkt1113](https://doi.org/10.1093/nar/gkt1113) PMID: [24234437](https://pubmed.ncbi.nlm.nih.gov/24234437/)
16. Basu SN, Kollu R, Banerjee-Basu S (2009) AutDB: a gene reference resource for autism research. *Nucleic Acids Res* 37: D832–D836. doi: [10.1093/nar/gkn835](https://doi.org/10.1093/nar/gkn835) PMID: [19015121](https://pubmed.ncbi.nlm.nih.gov/19015121/)
17. Flicek P, Ahmed I, Amode MR, Barrell D, Beal K, et al. (2013) Ensembl 2013. *Nucleic Acids Res* 41: D48–D55. doi: [10.1093/nar/gks1236](https://doi.org/10.1093/nar/gks1236) PMID: [23203987](https://pubmed.ncbi.nlm.nih.gov/23203987/)
18. Schwarz JM, Cooper DN, Schuelke M, Seelow D (2014) MutationTaster2: mutation prediction for the deep-sequencing age. *Nat Methods* 11: 361–362. doi: [10.1038/nmeth.2890](https://doi.org/10.1038/nmeth.2890) PMID: [24681721](https://pubmed.ncbi.nlm.nih.gov/24681721/)
19. Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, et al. (2014) A general framework for estimating the relative pathogenicity of human genetic variants. *Nat Genet* 46: 310–315. doi: [10.1038/ng.2892](https://doi.org/10.1038/ng.2892) PMID: [24487276](https://pubmed.ncbi.nlm.nih.gov/24487276/)
20. Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, et al. (2013) STRING v9.1: protein-protein interaction networks, with increased coverage and integration. *Nucleic Acids Res* 41: D808–D815. doi: [10.1093/nar/gks1094](https://doi.org/10.1093/nar/gks1094) PMID: [23203871](https://pubmed.ncbi.nlm.nih.gov/23203871/)
21. Jeste SS, Geschwind DH (2014) Disentangling the heterogeneity of autism spectrum disorder through genetic findings. *Nat Rev Neurol* 10: 74–81. doi: [10.1038/nrneurol.2013.278](https://doi.org/10.1038/nrneurol.2013.278) PMID: [24468882](https://pubmed.ncbi.nlm.nih.gov/24468882/)
22. Boccutto L, Lauri M, Sarasua SM, Skinner CD, Buccella D, et al. (2013) Prevalence of *SHANK3* variants in patients with different subtypes of autism spectrum disorders. *Eur J Hum Genet EJHG* 21: 310–316. doi: [10.1038/ejhg.2012.175](https://doi.org/10.1038/ejhg.2012.175) PMID: [22892527](https://pubmed.ncbi.nlm.nih.gov/22892527/)
23. Leblond CS, Nava C, Polge A, Gauthier J, Huguet G, et al. (2014) Meta-analysis of *SHANK* Mutations in Autism Spectrum Disorders: A Gradient of Severity in Cognitive Impairments. *PLoS Genet* 10: e1004580. Available: <http://dx.doi.org/10.1371/journal.pgen.1004580>. Accessed 12 September 2014. PMID: [25188300](https://pubmed.ncbi.nlm.nih.gov/25188300/)
24. Shcheglovitov A, Shcheglovitova O, Yazawa M, Portmann T, Shu R, et al. (2013) *SHANK3* and IGF1 restore synaptic deficits in neurons from 22q13 deletion syndrome patients. *Nature* 503: 267–271. doi: [10.1038/nature12618](https://doi.org/10.1038/nature12618) PMID: [24132240](https://pubmed.ncbi.nlm.nih.gov/24132240/)
25. Wang X, Bey AL, Chung L, Krystal AD, Jiang Y-H (2014) Therapeutic approaches for shankopathies. *Dev Neurobiol* 74: 123–135. doi: [10.1002/dneu.22084](https://doi.org/10.1002/dneu.22084) PMID: [23536326](https://pubmed.ncbi.nlm.nih.gov/23536326/)

26. Boycott KM, Vanstone MR, Bulman DE, MacKenzie AE (2013) Rare-disease genetics in the era of next-generation sequencing: discovery to translation. *Nat Rev Genet* 14: 681–691. doi: [10.1038/nrg3555](https://doi.org/10.1038/nrg3555) PMID: [23999272](https://pubmed.ncbi.nlm.nih.gov/23999272/)
27. Dewey FE, Grove ME, Pan C, Goldstein BA, Bernstein JA, et al (2014) Clinical interpretation and implications of whole-genome sequencing. *JAMA* 311: 1035–1045. doi: [10.1001/jama.2014.1717](https://doi.org/10.1001/jama.2014.1717) PMID: [24618965](https://pubmed.ncbi.nlm.nih.gov/24618965/)